A New Jersey federal court has delivered a significant judgment in favor of Sandoz Inc., awarding the pharmaceutical company just over $70 million in damages. The case revolved around allegations that United Therapeutics Corp. had obstructed the introduction of a generic version of a hypertension drug, an action that allegedly violated antitrust laws. In the decision issued Friday, the court sided with Sandoz’s accusations of anti-competitive practices designed to maintain monopolistic control over the drug’s market.
For further details, you can access the original report from Law360.